In this issue:
Immunogenicity of biosimilars in RA
Safety and efficacy of infliximab biosimilar BCD-055
Safety and efficacy of rituximab biosimilar CT-P10
Radiographic progression in RA: infliximab biosimilar vs originator
NOR-SWITCH study findings
Biosimilars in the UK – early real world data
Infliximab biosimilars and cost savings in Austria
Biologic DMARDs and biosimilars in AS in Nordic countries
Biosimilar transitioning in patients with rheumatic disease
Please login below to download this issue (PDF)